BRAIN CANCER

Latest News

FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade Glioma
FDA Approves Dabrafenib Plus Trametinib for Pediatric BRAF V600E-Mutant Low-Grade Glioma

March 16th 2023

Findings from the phase 2 Study CDRB436G2201 trial have led the FDA to approve dabrafenib combined with trametinib for pediatric patients with BRAF V600E-mutated low-grade glioma who require systemic therapy.

Vorasidenib Delays Disease Progression or Death in IDH+ Low-Grade Glioma
Vorasidenib Delays Disease Progression or Death in IDH+ Low-Grade Glioma

March 14th 2023

FDA Gives Orphan Drug Designation to Temferon for Glioblastoma Multiforme
FDA Gives Orphan Drug Designation to Temferon for Glioblastoma Multiforme

March 8th 2023

FDA Okays Phase 2 Study of Azeliragon for Patients With Glioblastoma
FDA Okays Phase 2 Study of Azeliragon for Patients With Glioblastoma

February 27th 2023

Present and Future Precision Medications Signal Promise for Adults With Glioma
Present and Future Precision Medications Signal Promise for Adults With Glioma

February 4th 2023

Video Series
Video Interviews

More News